APA (7th ed.) Citation

Di, X., Liu, C., Ni, L., Ye, W., Rong, Z., Zhang, R., . . . Liu, Y. (2022). Rationale and design for the study of recombinant human hepatocyte growth factor plasmid in the treatment of patients with chronic limb-threatening ischemia (HOPE CLTI): Randomized, placebo-controlled, double-blind, phase III clinical trials. The American heart journal, 254, 88-101. https://doi.org/10.1016/j.ahj.2022.08.007

Chicago Style (17th ed.) Citation

Di, Xiao, et al. "Rationale and Design for the Study of Recombinant Human Hepatocyte Growth Factor Plasmid in the Treatment of Patients with Chronic Limb-threatening Ischemia (HOPE CLTI): Randomized, Placebo-controlled, Double-blind, Phase III Clinical Trials." The American Heart Journal 254 (2022): 88-101. https://doi.org/10.1016/j.ahj.2022.08.007.

MLA (9th ed.) Citation

Di, Xiao, et al. "Rationale and Design for the Study of Recombinant Human Hepatocyte Growth Factor Plasmid in the Treatment of Patients with Chronic Limb-threatening Ischemia (HOPE CLTI): Randomized, Placebo-controlled, Double-blind, Phase III Clinical Trials." The American Heart Journal, vol. 254, 2022, pp. 88-101, https://doi.org/10.1016/j.ahj.2022.08.007.